This novel delivery method, applied to the inside of the cheek, offers a streamlined two-hour in-clinic treatment. Atai plans to begin a Phase 2 study by the end of 2024 to evaluate VLS-01's safety, ...
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new ...
I need to learn how to calm anxiety. Since I’m veering between ... to be spending my present reflecting on the past, such as social unrest in our nation’s capital. Nor will I be anticipating ...
Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder ... based companies plan to focus their efforts ...
Anxiety around the 2024 vote is causing some ... and nearly 36% said the outcome wouldn’t affect their plans. Businesses are also on alert, said Kelly Soderlund, a spokesperson for the online ...
Anxiety around the 2024 vote is causing some consumers to rethink where ... and nearly 36% said the outcome wouldn’t affect their plans. Businesses are also on alert, said Kelly Soderlund, a ...